David Tsur, CEO of Kamada, said: “Hercules’s debt financing will help fund a mixture of Kamada’s clinical programs and strategic priorities that enable our continued development and marketing of specialty, life-saving biopharmaceuticals designed to improve the quality of life of patients worldwide.”